ASCOPOST.COM: Keyword Density Checker

Total words: 3109 | 2-word phrases: 804 | 3-word phrases: 890 | 4-word phrases: 916

PAGE INFO

Title	Try to keep the title under 60 characters (28 characters) TAP Homepage - The ASCO Post
Description	Try to keep the meta description between 50 - 160 characters (0 characters)
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (16 characters) More Top Stories

#	Keyword	Frequency	Density
1	as reported in	4	0.45%
2	the phase iii	3	0.34%
3	reported in the	3	0.34%
4	the asco post	3	0.34%
5	food and drug	2	0.22%
6	vs standard of	2	0.22%
7	bpd vs pvd	2	0.22%
8	myeloma bpd vs	2	0.22%
9	multiple myeloma bpd	2	0.22%
10	or refractory multiple	2	0.22%
11	relapsed or refractory	2	0.22%
12	shown significantly improved	2	0.22%
13	standard of care	2	0.22%
14	lenvatinibpembrolizumab vs standard	2	0.22%
15	us food and	2	0.22%
16	asco annual meeting	2	0.22%
17	progressionfree survival with	2	0.22%
18	metastatic colorectal cancer	2	0.22%
19	roenn md fasco	2	0.22%
20	drug resistance in	2	0.22%
21	previously treated metastatic	2	0.22%
22	cancer previously treated	2	0.22%
23	jamie h von	2	0.22%
24	for advanced hepatocellular	2	0.22%
25	accelerated approval to	2	0.22%
26	refractory multiple myeloma	2	0.22%
27	overall survival benefit	2	0.22%
28	and colleagues the	2	0.22%
29	survival benefit with	2	0.22%
30	trial showed no	2	0.22%

#	Keyword	Frequency	Density
1	as reported in the	3	0.33%
2	or refractory multiple myeloma	2	0.22%
3	oncology center of excellence	2	0.22%
4	us food and drug	2	0.22%
5	overall survival benefit with	2	0.22%
6	relapsed or refractory multiple	2	0.22%
7	myeloma bpd vs pvd	2	0.22%
8	multiple myeloma bpd vs	2	0.22%
9	refractory multiple myeloma bpd	2	0.22%
10	lenvatinibpembrolizumab vs standard of	2	0.22%
11	significant overall survival benefit	1	0.11%
12	final analysis of the	1	0.11%
13	analysis of the phase	1	0.11%
14	of the phase iii	1	0.11%
15	leap017 trial showed no	1	0.11%
16	trial showed no significant	1	0.11%
17	showed no significant overall	1	0.11%
18	no significant overall survival	1	0.11%
19	bpd vs pvd study	1	0.11%
20	lenvatinib plus pembrolizumab vs	1	0.11%
21	the final analysis of	1	0.11%
22	pembrolizumab vs the standard	1	0.11%
23	vs the standard of	1	0.11%
24	the standard of care	1	0.11%
25	standard of care in	1	0.11%
26	of care in previously	1	0.11%
27	treated patients with mismatch	1	0.11%
28	patients with mismatch paolo	1	0.11%
29	plus pembrolizumab vs the	1	0.11%
30	and colleagues the final	1	0.11%
31	colleagues the final analysis	1	0.11%
32	d gordan advertisement previously	1	0.11%
33	as the approval of	1	0.11%
34	the approval of new	1	0.11%
35	approval of new first	1	0.11%
36	of new first and	1	0.11%
37	new first and secondline	1	0.11%
38	first and secondline immunotherapy	1	0.11%
39	combinations1 john d gordan	1	0.11%
40	john d gordan advertisement	1	0.11%

#	URL	Whois	Check
1	https://everwall.com/products/social-media-hubs/	Whois	everwall.com
2	https://conexiant.com/oncology	Whois	conexiant.com
3	https://hbside.com/Privacy-Policy/	Whois	hbside.com
4	https://www.asco.org	Whois	asco.org